促红细胞生成素治疗急性心肌梗死的研究进展

被引：3

作者：

杨巍

蔡彦

梅育嘉

周燕

机构：

[1] 红十字会医院

来源：

临床合理用药杂志 | 2011年 / 4卷 / 28期

关键词：

心肌梗死; 红细胞生成素; 贫血;

D O I：

10.15887/j.cnki.13-1389/r.2011.28.037

中图分类号：

R542.22 [];

学科分类号：

摘要：

促红细胞生成素是一种造血细胞生长因子,主要用于治疗多种原因引起的贫血。近来研究表明其具有多种非促造血方面的细胞保护作用,包括抗细胞凋亡、促血管生成等,在心肌梗死中发挥心肌细胞保护作用,这些作用可能是其治疗心肌梗死的治疗学基础。为临床心肌梗死的研究提供了新的思路和方向。

引用

页码：128 / 131

页数：4

共 9 条

[1]

Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs [J].

Hirata, Akio ;

Minammo, Tetsuo ;

Asanuma, Hiroshi ;

Fujita, Masashi ;

Wakeno, Masakatsu ;

Myoishi, Masafumi ;

Tsukamoto, Osamu ;

Okada, Ken-ichiro ;

Koyama, Hidekazu ;

Komamura, Kazuo ;

Takashima, Seiji ;

Shinozaki, Yoshiro ;

Mori, Hidezo ;

Shiraga, Masamichi ;

Kitakaze, Masafumi ;

Hori, Masatsugu .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (01) :176-184

[2]

Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318,000 units a day in acute myocardial infarction: Report of two cases [J].

Shin, DH ;

Kwon, YI ;

Choi, SI ;

Park, US ;

Lee, J ;

Shin, JH ;

Lee, JU ;

Kim, SG ;

Kim, JH ;

Lim, HK ;

Lee, BH ;

Kim, KS .

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (02) :222-224

[3]

Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window [J].

Moon, C ;

Krawczyk, M ;

Paik, D ;

Lakatta, EG ;

Talan, MI .

CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (04) :243-250

[4]

Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction [J].

van der Meer, P ;

Lipsic, E ;

Henning, RH ;

Boddeus, K ;

van der Velden, J ;

Voors, AA ;

van Veldhuisen, DJ ;

van Gilst, WH ;

Schoemaker, RG .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (01) :125-133

[5]

High Serum Erythropoietin Level Is Associated With Smaller Infarct Size in Patients With Acute Myocardial Infarction Who Undergo Successful Primary Percutaneous Coronary Intervention.[J].Shigeto Namiuchi;Yutaka Kagaya;Jun Ohta;Nobuyuki Shiba;Masafumi Sugi;Masayoshi Oikawa;Hiroyuki Kunii;Hidetsugu Yamao;Nobuo Komatsu;Mitsuru Yui;Hiroko Tada;Masahito Sakuma;Jun Watanabe;Toshikatsu Ichihara;Kunio Shirato.Journal of the American College of Cardiology.2005, 9

[6]

Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro [J].

Bullard, AJ ;

Yellon, DM .

CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (05) :333-336

[7]

Erythropoietin and VEGF exhibit equal angiogenic potential [J].

Jaquet, K ;

Krause, K ;

Tawakol-Khodai, M ;

Geidel, S ;

Kuck, KH .

MICROVASCULAR RESEARCH, 2002, 64 (02) :326-333

[8]

Suppression of mitochondrial GSK3βactivity by its Ser9-phosphorylation contributes to cardiomyocyte protection afforded by erythropoietin against oxidative stress-induced apoptosis..Ohori K;Miura T;Tanno M;et al;.Circulation.2007,

[9]

Delayed erythropoietin therapy reduces Post-MI cardiac remodeling only ate dose that mobilizes endo-thelial progenitor cells..Prunier F;Pfister O;Hadri L;et al;.Am J Physiol Heart Circ Physio.2007, 01

← 1 →